VP - 14637，维洛制药公司。
VP-14637 ViroPharma.
作者信息
McKimm-Breschkin J
机构信息
Biomolecular Research Institute, 343 Royal Parade, Parkville, VIC 3052, Australia.
出版信息
Curr Opin Investig Drugs. 2000 Dec;1(4):425-7.
VP-14637 is the lead compound in a series of low molecular weight viral replication inhibitors which are under preclinical investigation by ViroPharma for the potential treatment of RSV infection [322651]. Phase I trials designed to evaluate the safety and pharmacokinetic prpfile of VR-14637 in healthy human volunteers have begun [385870]. VP-14637 is most active against pneumoviruses and the available data suggest that it is an inhibitor of RSV viral fusion activity [363716], [361097].
VP - 14637是一系列低分子量病毒复制抑制剂中的先导化合物，ViroPharma正在对其进行临床前研究，以探讨其对呼吸道合胞病毒（RSV）感染的潜在治疗作用[322651]。旨在评估VR - 14637在健康人类志愿者中的安全性和药代动力学特征的I期试验已经开始[385870]。VP - 14637对肺病毒最为有效，现有数据表明它是RSV病毒融合活性的抑制剂[363716]，[361097]。
Zotero 插件